Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 2
1956 5
1957 2
1958 1
1959 1
1960 1
1961 3
1962 7
1963 4
1964 5
1965 8
1966 7
1967 6
1968 2
1969 9
1970 7
1971 12
1972 10
1973 5
1974 12
1975 8
1976 13
1977 13
1978 22
1979 19
1980 21
1981 32
1982 43
1983 49
1984 53
1985 46
1986 58
1987 68
1988 54
1989 52
1990 44
1991 50
1992 48
1993 43
1994 42
1995 40
1996 55
1997 36
1998 29
1999 32
2000 18
2001 38
2002 35
2003 39
2004 38
2005 57
2006 69
2007 64
2008 53
2009 49
2010 56
2011 55
2012 71
2013 78
2014 51
2015 76
2016 72
2017 63
2018 80
2019 82
2020 95
2021 124
2022 99
Text availability
Article attribute
Article type
Publication date

Search Results

2,377 results
Results by year
Filters applied: . Clear all
Page 1
Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension.
Briot K, Portale AA, Brandi ML, Carpenter TO, Cheong HI, Cohen-Solal M, Crowley RK, Eastell R, Imanishi Y, Ing S, Insogna K, Ito N, Jan de Beur S, Javaid MK, Kamenicky P, Keen R, Kubota T, Lachmann RH, Perwad F, Pitukcheewanont P, Ralston SH, Takeuchi Y, Tanaka H, Weber TJ, Yoo HW, Nixon A, Nixon M, Sun W, Williams A, Imel EA. Briot K, et al. Among authors: ito n. RMD Open. 2021 Sep;7(3):e001714. doi: 10.1136/rmdopen-2021-001714. RMD Open. 2021. PMID: 34548383 Free PMC article. Clinical Trial.
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
Insogna KL, Briot K, Imel EA, Kamenický P, Ruppe MD, Portale AA, Weber T, Pitukcheewanont P, Cheong HI, Jan de Beur S, Imanishi Y, Ito N, Lachmann RH, Tanaka H, Perwad F, Zhang L, Chen CY, Theodore-Oklota C, Mealiffe M, San Martin J, Carpenter TO; AXLES 1 Investigators. Insogna KL, et al. Among authors: ito n. J Bone Miner Res. 2018 Aug;33(8):1383-1393. doi: 10.1002/jbmr.3475. Epub 2018 Jun 26. J Bone Miner Res. 2018. PMID: 29947083 Free article. Clinical Trial.
Hepta-Histidine Inhibits Tau Aggregation.
Kondo K, Ikura T, Tanaka H, Fujita K, Takayama S, Yoshioka Y, Tagawa K, Homma H, Liu S, Kawasaki R, Huang Y, Ito N, Tate SI, Okazawa H. Kondo K, et al. Among authors: ito n. ACS Chem Neurosci. 2021 Aug 18;12(16):3015-3027. doi: 10.1021/acschemneuro.1c00164. Epub 2021 Jul 28. ACS Chem Neurosci. 2021. PMID: 34319089
Pulmonary artery pseudoaneurysm.
Takahashi S, Shigematsu R, Shiomi E, Ohori K, Ito N, Nakamura M. Takahashi S, et al. Among authors: ito n. Respirol Case Rep. 2019 Aug 1;7(7):e00468. doi: 10.1002/rcr2.468. eCollection 2019 Oct. Respirol Case Rep. 2019. PMID: 31388426 Free PMC article.
C3 glomerulopathy and current dilemmas.
Ito N, Ohashi R, Nagata M. Ito N, et al. Clin Exp Nephrol. 2017 Aug;21(4):541-551. doi: 10.1007/s10157-016-1358-5. Epub 2016 Nov 23. Clin Exp Nephrol. 2017. PMID: 27878657 Free PMC article. Review.
Transdifferentiation of human somatic cells by ribosome.
Ito N, Anam MB, Ahmad SAI, Ohta K. Ito N, et al. Dev Growth Differ. 2018 Jun;60(5):241-247. doi: 10.1111/dgd.12538. Epub 2018 May 29. Dev Growth Differ. 2018. PMID: 29845598 Free article. Review.
HMGB1 signaling phosphorylates Ku70 and impairs DNA damage repair in Alzheimer's disease pathology.
Tanaka H, Kondo K, Fujita K, Homma H, Tagawa K, Jin X, Jin M, Yoshioka Y, Takayama S, Masuda H, Tokuyama R, Nakazaki Y, Saito T, Saido T, Murayama S, Ikura T, Ito N, Yamamori Y, Tomii K, Bianchi ME, Okazawa H. Tanaka H, et al. Among authors: ito n. Commun Biol. 2021 Oct 11;4(1):1175. doi: 10.1038/s42003-021-02671-4. Commun Biol. 2021. PMID: 34635772 Free PMC article.
2,377 results